PAREXEL BROADENS GLOBAL REACH WITH NEW LOCATION IN INDIA
BOSTON, MA, June 18, 2007 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global bio/pharmaceutical services organization, today announced that it has opened a new location in Hyderabad, India. Through this new location, PAREXEL offers its clients a wide range of clinical research and data management services while deepening its long-term commitment in India.
“We are especially excited to be breaking ground in India’s 6th largest metropolis, which is quickly becoming an important biotechnology hub,” said Josef von Rickenbach, Chairman and Chief Executive Officer, PAREXEL. “With the addition of Hyderabad, PAREXEL provides biopharmaceutical and medical device companies with greater access to strength of our expertise, experience and innovation to help expedite getting their products to market faster.”
PAREXEL’s Hyderabad office is staffed by locally-based key management, and a team of highly skilled experts with extensive knowledge of India’s regulatory process. Clients can also benefit from PAREXEL’s existing alliances with regional academic institutions, strategic access to key investigator sites and established relationships with regulatory authorities.
“Last year, PAREXEL entered into a joint venture arrangement with Synchron, an India-based clinical research organization, to form PAREXEL International Synchron Private Limited, to provide a broad range of Phase II-IV clinical research services,” said Mark A. Goldberg, M.D., President of Clinical Research Services and Perceptive Informatics, PAREXEL International. “The opening of PAREXEL’s Hyderabad location was a natural next step to meet client demand in India for our services.”
For more information about PAREXEL, visit www.PAREXEL.com or visit Booth #724 at the DIA’s 43rd Annual Meeting.